Registration
 
All news
Top Stories
Editors' Picks
Crypto News
Financial News
Market Voices
Billionaires
Companies
Broker News
Regulators News
Ivan Andriyenko
Ivan Andriyenko

Protagonist Therapeutics wins FDA approval for ICOTYDE and joins Fast 500 ranking

Protagonist Therapeutics wins FDA approval for ICOTYDE and joins Fast 500 ranking
Protagonist wins FDA nod joins Fast 500

Protagonist Therapeutics has secured a major milestone with the FDA approval of its therapy ICOTYDE.

The company also announced its inclusion on the Nasdaq Tower in Times Square as a Fast 500 company, a status highlighting rapid growth and innovation among peers in North America. This dual achievement underscores Protagonist Therapeutics’ momentum and brings further validation to its strategy in the biotechnology sector.

The latest milestones achieved by Protagonist Therapeutics further build on the company’s trajectory established through its pioneering peptide technology, previously detailed in its groundbreaking platform developments. The FDA approval for ICOTYDE—now formally recognized—follows earlier regulatory progress that positioned the therapy as a first-line oral treatment for plaque psoriasis, as reflected in recent advancements in the approval process.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

How to build wealth from scratch in 3 practical steps
  • By Johnathan Maverick
  • 9 hours ago
How to build wealth from scratch in 3 practical steps
Editors' Picks
Kospi Index crash: Why South Korean market fell alongside AI stocks
  • By Eugene Komchuk
  • 12 hours ago
Kospi Index crash: Why South Korean market fell alongside AI stocks
Editors' Picks
Bitcoin or Ferrari: Which investment is better?
  • By Mira Kyivska
  • Yesterday
Bitcoin or Ferrari: Which investment is better?
Editors' Picks
All Editors' Top Picks

Latest Protagonist Therapeutics News

Protagonist Therapeutics stock attempts rebound above $95 after recent slide
  • By Dan Blystone
  • 04.06.2026
Protagonist Therapeutics stock attempts rebound above $95 after recent slide
Companies
#Protagonist Therapeutics
FDA clears Protagonist Therapeutics ICOTYDE as first-line oral plaque psoriasis treatment
  • By Igor Krasulya
  • 18.03.2026
FDA clears Protagonist Therapeutics ICOTYDE as first-line oral plaque psoriasis treatment
Companies
#Protagonist Therapeutics
Protagonist Therapeutics showcases pioneering peptide technology
  • By Elena Nikulina
  • 20.02.2026
Protagonist Therapeutics showcases pioneering peptide technology
Companies
#Protagonist Therapeutics
All Protagonist Therapeutics News
  • Johnathan Maverick
  • 9 hours ago
How to build wealth from scratch in 3 practical steps
  • Eugene Komchuk
  • 12 hours ago
Kospi Index crash: Why South Korean market fell alongside AI stocks
  • Mira Kyivska
  • Yesterday
Bitcoin or Ferrari: Which investment is better?
  • Mira Kyivska
  • 06.06.2026
Strategy sells Bitcoin: Small sale tests market confidence
  • Mikhail Vnuchkov
  • 05.06.2026
Ledger vs. Trezor: Search for ideal crypto wallet
  • Jose Antonio Gastelum
  • 29 min ago
Bitcoin continues volatile adoption phase, James Lavish notes
  • Daria Chernytska
  • 34 min ago
Sjuul Follings: H1DR4 token gaining traction after recent launch
  • Yaroslav Dmytrenko
  • 34 min ago
Keith McCullough: DRAM and QTUM record strong gains in daily bounceback
  • Hanna Syniavska
  • 39 min ago
Bitcoin innovators come together in Norway, Alex Gladstein notes
  • Andreas Kristo
  • 40 min ago
Anas Alhajji: Declining global oil demand raises market balance questions
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.
Top News
  • Eugene Komchuk
  • 4 hours ago
Sam Bankman-Fried formally seeks pardon from Trump
Sam Bankman-Fried formally seeks pardon from Trump
  • Ivan Andriyenko
  • 7 hours ago
Hayes dumps WLD days after Maelstrom's bullish call
Hayes dumps WLD days after Maelstrom's bullish call
  • Hanna Syniavska
  • 10 hours ago
Powell warns Trump pressure on Fed could threaten markets
Powell warns Trump pressure on Fed could threaten markets
  • Igor Krasulya
  • 11 hours ago
Nvidia bets on South Korea in AI infrastructure race
Nvidia bets on South Korea in AI infrastructure race
  • Olga Shendetskaya
  • 12 hours ago
Oil rises above $97 after new Israel-Iran exchange of strikes
Oil rises above $97 after new Israel-Iran exchange of strikes
Live News
  • Anton Kharitonov
  • Now
Alphabet decline intensifies amid record AI investment
  • Anton Kharitonov
  • Now
Microsoft declines amid AI expectation reset, but fundamentals remain strong
  • Dmytro Kharkov
  • Now
Snowflake tests post-earnings breakout as AI rally faces first challenge
  • Anton Kharitonov
  • Now
Apple under pressure as investor skepticism grows
  • Dmytro Kharkov
  • Now
Nvidia tests key support as Jensen Huang calls AI sell-off a buying opportunity
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR